Samarium
AboutServices

samarium.dev
a software development company

Energy Fuels Opens White Mesa Mill to Public

MedicalOct 4, 2025

United States

Energy Fuels Inc. will host a two-day open house at its White Mesa Mill in Blanding, Utah on October 14–15, 2025, offering a rare public look inside the only fully licensed, operating conventional uranium and rare-earths processing plant in the Western Hemisphere.

Attendees will tour integrated milling operations that recover uranium, vanadium, rare earth elements (REEs), titanium, zirconium and medical isotopes from diverse feedstocks. Company experts will demonstrate process flows, separation techniques and recent advances in extraction and refining that support mine-to-market domestic supply chains for nuclear power, electric-vehicle magnets, wind turbines, medical imaging and defense components.

The program includes facility tours, expert panels on critical-minerals policy and technology, and technology showcases featuring pilot and commercial-scale innovations. Scheduled events run October 14 from 10:00 AM to 3:00 PM and October 15 from 10:00 AM to 2:00 PM, with an additional Milling at the Mill tour from 4:00 PM to 6:00 PM on October 15. Registration is open to the public, industry stakeholders and policymakers seeking insights into U.S. processing capacity and clean-energy supply-chain resilience.

Related Articles

China's Sichuan Discovery Fuels Rare Earth Medical Breakthroughs
4/3/2026

A massive new rare earth deposit in Sichuan Province strengthens China's dominance in medical imaging, diagnostics, and cancer therapies, enabling innovations like low-dose radiosensitizers and advanced MRI nanoprobes.

Radiopharmaceutical Breakthrough: Actinium-225 Advances Targeted Cancer Treatment
3/27/2026

Mayo Clinic has become the first U.S. organization to treat breast cancer patients with actinium-225 DOTATATE, a potent rare-earth radiopharmaceutical offering alpha-particle precision therapy for metastatic cancers. This advancement demonstrates how rare earth isotopes are revolutionizing targeted radiation therapy by delivering lethal radiation directly to tumor cells while sparing healthy tissue.

Bayer's Gadoquatrane Redefines MRI Contrast with Ultra-Low Gadolinium Dosing
3/20/2026

Bayer has developed a breakthrough MRI contrast agent that requires 60% less gadolinium than standard treatments while maintaining diagnostic quality, addressing environmental concerns and sustainability in medical imaging.

Thulium Nanoparticles Revolutionize Cancer Radiotherapy
3/13/2026

Breakthrough research reveals thulium-based nanoparticles that enhance low-dose X-ray therapy by generating oxygen and reactive oxygen species, targeting tumors more effectively while reducing side effects.

Neodymium Nanomedicine Illuminates Eye Cancer Treatment
2/27/2026

Researchers have pioneered a neodymium-doped nanomedicine that revolutionizes choroidal melanoma therapy by enabling real-time imaging and targeted treatment, eliminating autofluorescence for precise tumor visualization while activating multiple cell-killing mechanisms.